While CEO and COO open-market buys are strong signals, their absence isn't fatal. In Fiserv's case, recent buys from the new CFO, Chief Legal Officer, and a director with a history of successful insider trades provide critical, albeit more nuanced, confirmation of a turnaround from key oversight roles.

In biotech, CEO insider buys are common and not very predictive. The real signal comes from the rest of the management team, especially the CFO. CFOs are typically more bearish and financially disciplined, so their decision to buy company stock is a particularly strong vote of confidence.

A CFO's large personal investment, despite a significant subsequent stock price decline, indicates strong belief in a turnaround. Newell's strategy of cutting unprofitable product lines to boost profitability is being misread by the market as just falling revenue, creating a potential value opportunity.

Nomad's new CEO has followed a classic script: take over, reset expectations by highlighting problems like underutilized plants, and then build anticipation for a new strategy to be unveiled at an upcoming analyst day. This "kitchen sinking" often creates an attractive entry point for investors before the turnaround story is fully priced in.

In a rare display of conviction, former Lifco CEO Frederick Carlson, after being fired over a bonus dispute, immediately bought more shares. This act demonstrated immense faith in the company's durable culture and the abilities of his successor, validating the strength of the organization beyond any single leader.

After personal tragedies caused a seed round to collapse, the founder's openness with investors and decision to self-fund the company demonstrated extreme resilience. This convinced his team to stay and even brought back previous investors, showcasing that founder conviction is a powerful signal.

Insider buying in biotech isn't just a short-term trading signal around an event. The quantitative analysis shows its predictive power lasts for months after the transaction. This implies insiders are buying based on a durable, fundamental belief in the company's science and trajectory, not just upcoming news.

When founders invest their own money, it signals an unparalleled level of commitment and belief. This act serves as a powerful 'magnetic pull,' de-risking the opportunity in the eyes of external investors and making them significantly more likely to commit their own capital.

Warren Buffett's successor, Greg Abel, is investing his entire $15 million salary into Berkshire Hathaway stock. This is a powerful form of "eating your own dog food" that signals ultimate confidence in the company's future to the market, aligning his personal financial success directly with shareholder outcomes.